Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Pursues ‘Invented In China’ Goal At New Shanghai Hub

This article was originally published in PharmAsia News

Executive Summary

Helped by Shanghai’s supportive policies to attract talent to back its transformation into a global innovation center by 2030, Novartis recently opened its global third-largest R&D center in the city, as part of a strategy to develop new compounds locally for the worldwide market by tapping into local expertise.

You may also be interested in...



Big Pharma CEOs Descend On China: What’s The Likely Agenda?

In a major show of force, four global pharma CEOs are heading to China to participate in high-level open and closed-door discussions that are expected to include a range of policy and regulatory reform topics. Tapping into China’s push to improve health and develop an innovation-driven economy may provide new openings for their voices to be heard.

Asia Attracts Manufacturing Capital As Companies Eye Expanding Needs

Life science and pharma companies have been actively investing in Asia over the past month as they look to increase regional manufacturing capacities to tap into burgeoning markets and meet rising demand for new technologies, biologics and high-quality products, while Chinese firms have also been expanding their international presence.

Key Role For China As Sanofi’s Emerging Markets Business Grows

Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.

Topics

Related Companies

UsernamePublicRestriction

Register

SC089563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel